Zhang H X, Guo L P, Zhou L, Wei W, Wang B M
Department of Gastroenterology and Hepotology, Tianjin Medical University General Hospital, Tianjin 300052, China.
Zhonghua Gan Zang Bing Za Zhi. 2018 Feb 20;26(2):155-159. doi: 10.3760/cma.j.issn.1007-3418.2018.02.017.
The treatment of autoimmune hepatitis is similar to that of rheumatic immune disease, which requires the use of hormones and immunosuppressive agents to induce and maintain remission therapy. As one of the most common diseases of rheumatology, rheumatoid arthritis has a definite treatment strategy and gradually becomes a new concept of rheumatoid disease. However, the current treatment of autoimmune hepatitis is still lack of standard compliance treatment strategies, and for the disease activity and immunosuppressive treatment of the efficacy of no uniform standard evaluation criteria, there is no clear evidence of the need to increase the hormone dose or the timing of treatment for patients with substandard treatment, so we consider the standard treatment of autoimmune hepatitis from the experience of rheumatoid arthritis of rheumatism, in order to provide reference for perfecting the standardized treatment of autoimmune hepatitis.
自身免疫性肝炎的治疗与风湿免疫性疾病相似,需要使用激素和免疫抑制剂来诱导和维持缓解治疗。类风湿关节炎作为风湿病最常见的疾病之一,有明确的治疗策略,并逐渐成为类风湿病的一个新观念。然而,目前自身免疫性肝炎的治疗仍缺乏规范的依从性治疗策略,对于疾病活动度及免疫抑制治疗疗效尚无统一的标准评估标准,对于治疗不达标患者也无明确证据表明需要增加激素剂量或调整治疗时机,因此我们从风湿病类风湿关节炎的经验来思考自身免疫性肝炎的规范治疗,以期为完善自身免疫性肝炎的规范化治疗提供参考。